In vitro anti-influenza A activity of interferon (IFN)-λ1 combined with IFN-β or oseltamivir carboxylate
Identifieur interne : 001076 ( Main/Exploration ); précédent : 001075; suivant : 001077In vitro anti-influenza A activity of interferon (IFN)-λ1 combined with IFN-β or oseltamivir carboxylate
Auteurs : Natalia A. Ilyushina [États-Unis] ; Raymond P. Donnelly [États-Unis]Source :
- Antiviral research [ 0166-3542 ] ; 2014.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Influenza viruses, which can cross species barriers and adapt to new hosts, pose a constant potential threat to human health. The influenza pandemic of 2009 highlighted the rapidity with which an influenza virus can spread worldwide. Currently available antivirals have a number of limitations against influenza, and novel antiviral strategies, including novel drugs and drug combinations, are urgently needed. Here, we evaluated the in vitro effects of interferon (IFN)-β, IFN-λ1, oseltamivir carboxylate (a neuraminidase (NA) inhibitor), and combinations of these agents against two seasonal (i.e., H1N1 and H3N2) influenza A viruses. We observed that A/California/04/09 (H1N1) and A/Panama/2007/99 (H3N2) isolates were equally sensitive to the antiviral activity of IFN-β and oseltamivir carboxylate in A549 and Calu-3 cells. In contrast, IFN-λ1 exhibited substantially lower protective potential against the H1N1 strain (64-1030-fold ↓, P < 0.05), and was ineffective against H3N2 virus in both cell lines. Three dimensional analysis of drug-drug interactions revealed that IFN-λ1 interacted with IFN-β and oseltamivir carboxylate in an additive or synergistic manner, respectively, to inhibit influenza A virus replication in human airway epithelial cells. Overall, the present study demonstrated that anti-influenza agents with different mechanisms of action (e.g., a NA inhibitor combined with IFN-λ1) exerted a significantly greater (P < 0.05) synergistic effect compared to co-treatment with drugs that target the same signaling pathway (i.e., IFN-β plus IFN-λ1) in vitro. Our findings provide support for the combined use of interferon plus oseltamivir as a potential means for treating influenza infections.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000025
- to stream PascalFrancis, to step Curation: 001D94
- to stream PascalFrancis, to step Checkpoint: 000085
- to stream Main, to step Merge: 001086
- to stream Main, to step Curation: 001076
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">In vitro anti-influenza A activity of interferon (IFN)-λ1 combined with IFN-β or oseltamivir carboxylate</title><author><name sortKey="Ilyushina, Natalia A" sort="Ilyushina, Natalia A" uniqKey="Ilyushina N" first="Natalia A." last="Ilyushina">Natalia A. Ilyushina</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Division of Therapeutic Proteins, Center for Drug Evaluation and Research, Food and Drug Administration</s1><s2>Silver Spring, MD 20993</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Donnelly, Raymond P" sort="Donnelly, Raymond P" uniqKey="Donnelly R" first="Raymond P." last="Donnelly">Raymond P. Donnelly</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Division of Therapeutic Proteins, Center for Drug Evaluation and Research, Food and Drug Administration</s1><s2>Silver Spring, MD 20993</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">14-0273479</idno><date when="2014">2014</date><idno type="stanalyst">PASCAL 14-0273479 INIST</idno><idno type="RBID">Pascal:14-0273479</idno><idno type="wicri:Area/PascalFrancis/Corpus">000025</idno><idno type="wicri:Area/PascalFrancis/Curation">001D94</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000085</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000085</idno><idno type="wicri:doubleKey">0166-3542:2014:Ilyushina N:in:vitro:anti</idno><idno type="wicri:Area/Main/Merge">001086</idno><idno type="wicri:Area/Main/Curation">001076</idno><idno type="wicri:Area/Main/Exploration">001076</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">In vitro anti-influenza A activity of interferon (IFN)-λ1 combined with IFN-β or oseltamivir carboxylate</title><author><name sortKey="Ilyushina, Natalia A" sort="Ilyushina, Natalia A" uniqKey="Ilyushina N" first="Natalia A." last="Ilyushina">Natalia A. Ilyushina</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Division of Therapeutic Proteins, Center for Drug Evaluation and Research, Food and Drug Administration</s1><s2>Silver Spring, MD 20993</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Donnelly, Raymond P" sort="Donnelly, Raymond P" uniqKey="Donnelly R" first="Raymond P." last="Donnelly">Raymond P. Donnelly</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Division of Therapeutic Proteins, Center for Drug Evaluation and Research, Food and Drug Administration</s1><s2>Silver Spring, MD 20993</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author></analytic><series><title level="j" type="main">Antiviral research</title><title level="j" type="abbreviated">Antivir. res.</title><idno type="ISSN">0166-3542</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Antiviral research</title><title level="j" type="abbreviated">Antivir. res.</title><idno type="ISSN">0166-3542</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral</term><term>Beta interferon</term><term>Combined treatment</term><term>Cytokine</term><term>Drug combination</term><term>In vitro</term><term>Influenza A</term><term>Influenza A virus</term><term>Oseltamivir</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>In vitro</term><term>Grippe A</term><term>Cytokine</term><term>Interféron bêta</term><term>Oséltamivir</term><term>Virus grippal A</term><term>Traitement associé</term><term>Association médicamenteuse</term><term>Antiviral</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Influenza viruses, which can cross species barriers and adapt to new hosts, pose a constant potential threat to human health. The influenza pandemic of 2009 highlighted the rapidity with which an influenza virus can spread worldwide. Currently available antivirals have a number of limitations against influenza, and novel antiviral strategies, including novel drugs and drug combinations, are urgently needed. Here, we evaluated the in vitro effects of interferon (IFN)-β, IFN-λ1, oseltamivir carboxylate (a neuraminidase (NA) inhibitor), and combinations of these agents against two seasonal (i.e., H1N1 and H3N2) influenza A viruses. We observed that A/California/04/09 (H1N1) and A/Panama/2007/99 (H3N2) isolates were equally sensitive to the antiviral activity of IFN-β and oseltamivir carboxylate in A549 and Calu-3 cells. In contrast, IFN-λ1 exhibited substantially lower protective potential against the H1N1 strain (64-1030-fold ↓, P < 0.05), and was ineffective against H3N2 virus in both cell lines. Three dimensional analysis of drug-drug interactions revealed that IFN-λ1 interacted with IFN-β and oseltamivir carboxylate in an additive or synergistic manner, respectively, to inhibit influenza A virus replication in human airway epithelial cells. Overall, the present study demonstrated that anti-influenza agents with different mechanisms of action (e.g., a NA inhibitor combined with IFN-λ1) exerted a significantly greater (P < 0.05) synergistic effect compared to co-treatment with drugs that target the same signaling pathway (i.e., IFN-β plus IFN-λ1) in vitro. Our findings provide support for the combined use of interferon plus oseltamivir as a potential means for treating influenza infections.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Maryland</li></region></list><tree><country name="États-Unis"><region name="Maryland"><name sortKey="Ilyushina, Natalia A" sort="Ilyushina, Natalia A" uniqKey="Ilyushina N" first="Natalia A." last="Ilyushina">Natalia A. Ilyushina</name></region><name sortKey="Donnelly, Raymond P" sort="Donnelly, Raymond P" uniqKey="Donnelly R" first="Raymond P." last="Donnelly">Raymond P. Donnelly</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001076 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001076 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:14-0273479
|texte= In vitro anti-influenza A activity of interferon (IFN)-λ1 combined with IFN-β or oseltamivir carboxylate
}}
| This area was generated with Dilib version V0.6.34. |  |